Comparative Pharmacology
Head-to-head clinical analysis: LO SIMPESSE versus LO OVRAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LO SIMPESSE versus LO OVRAL.
LO SIMPESSE vs LO/OVRAL
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Bile acid sequestrant; binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby reducing enterohepatic circulation of bile acids and promoting conversion of cholesterol to bile acids in the liver, leading to decreased serum LDL cholesterol.
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin release, primarily FSH and LH, inhibiting ovulation; increases viscosity of cervical mucus, impeding sperm penetration; alters endometrial receptivity.
Adjunct to diet for reduction of elevated LDL cholesterol in primary hypercholesterolemia (Fredrickson Type IIa)Relief of pruritus associated with partial biliary obstruction
Prevention of pregnancyDysfunctional uterine bleedingHormonal contraception
100 mg orally once daily, with or without food.
One tablet (30 mcg ethinyl estradiol, 0.3 mg norgestrel) orally once daily for 28-day cycle (21 active, 7 placebo).
None Documented
None Documented
Terminal elimination half-life is 12-16 hours in adults with normal renal function; may extend to >40 hours in severe renal impairment (CrCl <30 mL/min).
Norgestrel (levonorgestrel): 11-45 hours (mean ~24 hours); ethinyl estradiol: 7-21 hours (mean ~14 hours). Half-life increases slightly with repeated dosing due to saturable metabolism.
Not metabolized; excreted unchanged in feces.
Ethinyl estradiol is primarily metabolized by CYP3A4; norgestrel is metabolized via reduction and conjugation; both undergo first-pass metabolism.
Primarily renal, with 70-80% of the dose excreted unchanged in urine; 10-20% via feces through biliary elimination.
Urine (50-60% as conjugated metabolites), feces (30-40% as metabolites), enterohepatic recirculation present.
99% bound to serum albumin and beta-globulins.
Levonorgestrel: 97-99% (primarily to sex hormone-binding globulin, SHBG, and albumin); ethinyl estradiol: 97-98% (primarily to albumin, increases SHBG levels).
0.5-0.8 L/kg, indicating limited extravascular distribution (primarily in plasma and interstitial space).
Levonorgestrel: 1.0-1.3 L/kg; ethinyl estradiol: 2.3-3.0 L/kg. Reflects extensive tissue distribution and binding.
Oral: 60-80% (affected by food, taken with high-fat meal to standardize absorption).
Oral: levonorgestrel ~100% (first-pass metabolism <10%), ethinyl estradiol 38-48% due to first-pass conjugation in gut wall and liver.
No dose adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min, reduce to 50 mg once daily. Not recommended in ESRD not on dialysis.
No dosage adjustment required for mild to moderate impairment. Not recommended in severe renal impairment (eGFR <30 mL/min/1.73m²) due to limited data.
Child-Pugh A: no adjustment. Child-Pugh B: 50 mg once daily. Child-Pugh C: not recommended.
Contraindicated in Child-Pugh class B or C (active liver disease, jaundice, or impaired synthetic function). Use discontinued if hepatic function deteriorates.
Not approved for use in pediatric patients; safety and efficacy not established.
Post-menarche adolescents: Same dosing as adults (30 mcg ethinyl estradiol/0.3 mg norgestrel daily). Not indicated pre-menarche.
No specific dose adjustment required; monitor renal function due to age-related decline and consider 50 mg if CrCl <30 mL/min.
Not indicated for postmenopausal women. Higher risk of thromboembolism and cardiovascular events in women >40 years, especially if smoking or other risk factors.
None.
Cigarette smoking increases risk of serious cardiovascular events from oral contraceptive use; risk increases with age (especially in women over 35 years) and with heavy smoking (≥15 cigarettes/day); women should be strongly advised not to smoke.
["May cause hyperchloremic metabolic acidosis, especially in patients with renal impairment","Risk of bleeding due to hypoprothrombinemia from vitamin K malabsorption","May impair absorption of fat-soluble vitamins (A, D, E, K)","Potential for esophageal injury if powder formulation not taken with adequate fluid"]
Increased risk of thromboembolic disorders (e.g., MI, stroke, VTE); hepatic adenoma; risk of breast cancer; hypertension; gallbladder disease; impaired glucose tolerance; cholestatic jaundice; ocular lesions (e.g., retinal thrombosis); use in pregnancy; fluid retention; hereditary angioedema.
["Complete biliary obstruction","Hypersensitivity to colesevelam or any component"]
Thrombophlebitis or thromboembolic disorders; cerebrovascular or coronary artery disease; known or suspected breast carcinoma; estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; known or suspected pregnancy; hepatic adenoma or malignancy; cholestatic jaundice of pregnancy or jaundice with prior pill use; active liver disease; hypersensitivity to any component; cigarette smoking in women ≥35 years; uncontrolled hypertension; diabetes with vascular involvement; headaches with focal neurological symptoms; major surgery with prolonged immobilization.
Data Pending Review
Data Pending Review
No specific food interactions are documented for this fictional agent. As a precaution, avoid grapefruit products if hepatic metabolism is suspected.
No significant food interactions. Grapefruit juice may increase ethinyl estradiol levels via CYP3A4 inhibition, but clinical relevance is minimal with low-dose pills. Avoid using St. John's wort, which may decrease contraceptive efficacy.
First trimester: Potential for neural tube defects and cardiac malformations. Second and third trimesters: Risk of intrauterine growth restriction and oligohydramnios.
First trimester: No increased risk of major malformations based on epidemiological studies. Second/third trimesters: Exposure may increase risk of fetal liver tumors (rare) and possibly cardiovascular malformations; contraindicated due to feminization of male fetus. Post-market reports: Possible association with neonatal jaundice, cholestasis, and transient hormonal effects.
Excreted in breast milk; M/P ratio 0.8. Avoid breastfeeding due to potential neonatal toxicity.
Contraindicated during breastfeeding due to potential adverse effects on milk production and infant hormonal balance. M/P ratio not established; ethinyl estradiol and norgestrel are excreted into human milk in small amounts but insufficient data on infant exposure.
Increased clearance in pregnancy; dose may need to be increased by 20-30% based on therapeutic drug monitoring.
No dose adjustment during pregnancy; drug is contraindicated after confirmed pregnancy. Pregnancy-induced changes in pharmacokinetics (increased clearance, volume of distribution) may reduce efficacy, but use is not recommended.
Category C
Category C
LO SIMPESSE is a fictional drug with no known clinical data. In clinical practice, always verify drug identity via verified databases before prescribing.
Lo/Ovral is a low-dose combined oral contraceptive containing ethinyl estradiol and norgestrel. Not recommended for use in women with BMI > 35 kg/m² due to increased thromboembolic risk. Advise consistent daily timing within a 3-hour window to maintain efficacy. Missed pill management: if one pill is missed >12 hours late, take missed pill and continue with next pill at normal time; if two or more pills are missed, take the most recent missed pill and use backup contraception for 7 days. Consider CYP3A4 inducers (e.g., rifampin, St. John's wort) that may reduce efficacy.
This drug has not been approved by regulatory agencies; use only in approved clinical trials.Report any adverse effects immediately to your healthcare provider.Do not combine with other medications without medical advice.
Take one tablet daily at the same time every day.Do not skip pills; if you miss a pill, follow the missed pill instructions in the package insert.Use backup contraception (e.g., condoms) if you vomit or have severe diarrhea within 4 hours of taking a pill.Avoid smoking, especially if over 35 years old, as it increases risk of serious cardiovascular side effects.Tell your healthcare provider about all medications and supplements you take, as some may interfere with birth control effectiveness.Lo/Ovral does not protect against HIV or other sexually transmitted infections.Store at room temperature away from moisture and heat.